Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

17.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.3K
Antibody Structure and Classes01:25

Antibody Structure and Classes

8.4K
Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
8.4K
Antibody Structure01:10

Antibody Structure

65.4K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peptide Thioester and Triazole Derivatives Through On-Resin Dual-Modification of Peptide Thiosulfonates.

Angewandte Chemie (International ed. in English)·2026
Same author

The evolving role of cytokines for CAR-T cell manufacturing and beyond.

Nature biomedical engineering·2026
Same author

Impact of ASO conjugation and receptor binding affinity on intracellular transport of mono- and bispecific TfR- and CD98-Brainshuttle<sup>TM</sup> variants.

mAbs·2026
Same author

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal for immunotherapy of cancer·2026
Same author

Target receptor expression dictates the selective intra-tumoral targeting of CD8<sup>+</sup> T cells by eciskafusp alfa in matched PBMCs and TILs from CPI-naïve patients.

Frontiers in immunology·2026
Same author

Tobemstomig, a Novel Bispecific Antibody, Preferentially Blocks PD-1 and LAG-3 on CD8 TILs to Expand Stem-like T Cells for Sustained Tumor Control.

Cancer research communications·2026

Related Experiment Video

Updated: Jan 19, 2026

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

11.0K

Special Issue: Monoclonal Antibodies.

Christian Klein1

  • 1Roche Pharmaceutical Research & Early Development, 8952 Schlieren, Switzerland. christian.klein.ck1@roche.com.

Antibodies (Basel, Switzerland)
|September 24, 2019
PubMed
Summary

Monoclonal antibodies are key therapeutics for treating cancer, autoimmune disorders, and infectious diseases. These engineered proteins offer targeted treatments with significant clinical impact.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Monoclonal antibodies (mAbs) are critical biologics in modern medicine.
  • They are employed across diverse therapeutic areas, including oncology, autoimmune diseases, metabolic disorders, and infectious diseases.
  • The clinical utility of mAbs stems from their high specificity and targeted action.

Discussion:

  • The development of monoclonal antibodies has revolutionized treatment paradigms.
  • Their targeted mechanisms offer improved efficacy and potentially reduced side effects compared to conventional therapies.
  • Ongoing research focuses on optimizing mAb engineering for enhanced therapeutic profiles.

Key Insights:

  • Monoclonal antibodies are established treatments for numerous conditions.

More Related Videos

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.6K
Author Spotlight: Detecting Low-Abundant Host Cell Proteins in Drug Products Using Enrichment Beads and Limited Digestion
09:45

Author Spotlight: Detecting Low-Abundant Host Cell Proteins in Drug Products Using Enrichment Beads and Limited Digestion

Published on: January 19, 2024

2.8K

Related Experiment Videos

Last Updated: Jan 19, 2026

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood
13:14

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

11.0K
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.6K
Author Spotlight: Detecting Low-Abundant Host Cell Proteins in Drug Products Using Enrichment Beads and Limited Digestion
09:45

Author Spotlight: Detecting Low-Abundant Host Cell Proteins in Drug Products Using Enrichment Beads and Limited Digestion

Published on: January 19, 2024

2.8K
  • Their application spans a wide range of clinical specialties.
  • The specificity of mAbs allows for precise therapeutic intervention.

    • Outlook:

    • Future directions include the development of novel mAb formats and combination therapies.
    • Expanding applications in previously untreatable diseases are anticipated.
    • Personalized medicine approaches utilizing mAbs are a growing area of interest.